Navigation Links
Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection

other agents in this challenging setting."

Preclinical studies suggest that Valortim has the potential to provide significant protection against anthrax infection when administered prophylactically (prior to the emergence of symptoms of anthrax infection) and also may increase survival when administered therapeutically (once symptoms become evident). In these studies, Valortim has been shown to protect both rabbits and monkeys against the lethal effects of anthrax infection when administered at the time of exposure, at doses as low as 1.0 mg/kg. When administered to rabbits after the development of symptoms, Valortim also improved survival as late as 48 hours post-exposure as compared to controls.

"We believe that there are distinct characteristics of Valortim that make it an ideal choice for military and civilian protection against an anthrax bioterrorist attack," commented David P. Wright, President and Chief Executive Officer of PharmAthene. "As our Phase I results have demonstrated, a single intramuscular dose of Valortim produces levels of antibodies in humans that correspond to protective levels in animal models and is well tolerated. Based on the impressive human safety and animal efficacy data collected to date, we believe that Valortim could meet the needs of the U.S. Government and could ultimately be selected for inclusion in the Strategic National Stockpile to provide protection to the American public."

About Valortim

Valortim (MDX-1303) is a fully human antibody designed to protect against anthrax infection, including inhalation anthrax, the most lethal form of illness in humans caused by the Bacillus anthracis bacterium. The investigational antibody is designed to target a protein component known as the anthrax protective antigen (PA) of the lethal toxin complex produced by the bacterium. The anthrax protective antigen is believed to initiate the onset of the illness by attaching to cells in the infected person, and then is
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
2. Cethromycin Shown Effective Against Anthrax in Study
3. Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic Effect in New Primate Model of Established Anthrax Infection
4. Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal Antibody IMC-A12 Presented at ASCO
5. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
6. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
7. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
8. Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in Cancer Animal Models
9. Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response
10. Mymetics HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model
11. La Jolla Pharmaceutical Provides Update on Interim Antibody Results From Riquent Lupus Phase 3 Trial

Post Your Comments:
(Date:11/7/2009).... 7 Patients reported C1-esterase ...rapy in treating acute swelling attacks at any bod...order, according to data presented today at the 20...ology (ACAAI) Annual Meeting. The results come fro...parallel with the ongoing, prospective, open label...
(Date:11/6/2009)... SCOLR Pharma, Inc. (Ame... three and nine months ended September 30, 2009. ... and CEO, said, "We continue to advance discussion...lation. Several potential partners have committed ...nal resources as they evaluate the potential comme...
(Date:11/6/2009)...ewswire-FirstCall/ -- Recession in domestic and in... Allied Healthcare Products in the first quarter o..., Sales declines pushed Allied into a loss for the...$745,000, or negative 9 cents per share, compared ..., or 3 cents per share. ,, Sales fell about 21...
Breaking Medicine Technology:Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care 2Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care 3SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 2SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 3SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 4SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 5SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 6SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 7SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 8SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 9Recession Continues to Depress Sales at Allied Healthcare Products 2Recession Continues to Depress Sales at Allied Healthcare Products 3Recession Continues to Depress Sales at Allied Healthcare Products 4Recession Continues to Depress Sales at Allied Healthcare Products 5Recession Continues to Depress Sales at Allied Healthcare Products 6Partnership for Prescription Assistance Prepared To Help Virginia Workers Hurt by Recession 55567 1Partnership for Prescription Assistance Prepared To Help Virginia Workers Hurt by Recession 55567 2Partnership for Prescription Assistance Prepared To Help Virginia Workers Hurt by Recession 55567 3Partnership for Prescription Assistance Prepared To Help Virginia Workers Hurt by Recession 55567 4Fat Fighting Chemical Holds Promise 55564 1Fat Fighting Chemical Holds Promise 55564 2ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 1ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 2ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 3ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 4ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 5ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 6ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 7ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 8ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 9ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 10ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 11ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 12ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 13ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 14ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 15
...hKline (NYSE: GSK ),announced positive safety an...,controlled ITP Study with Eltrombopag), a Phase I...th chronic immune (idiopathic) thrombocytopenic,pu... therapies. Patients,receiving PROMACTA were eight...in platelet counts between 50,000 to 400,000/micro...
...he Local Treatment of Oral Candidiasis in Immunosu...J., Dec. 5 RHEI Pharmaceuticals, Inc. today annou... locally active antifungal with low dose miconazol...iated in China. This will be the last clinical tr...cation (NDA) to the State Food and Drug Administra...
Other Medicine Technology:GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 2GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 3GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 4GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 5GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 6GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 7GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 8RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China 2
(Date:11/9/2009)...t of seniors have changed Medicare plans, 16 perce...nd improved coverage among biggest drivers ,to cha... Belleville, Il (Vocus) No...have changed their Medicare plan since becoming el...ey are likely to or are considering switching plan...
(Date:11/9/2009)...for breast cancer are at higher risk of cancer rec...he December 15, 2009 issue of Cancer , a peer-rev...study,s results indicate that breast cancer patien...therapies following surgery, such as radiation. ,...breast tissue are at increased risk of breast canc...
(Date:11/8/2009)...USNewswire/ -- The American Public Health Associat...ovisions in the health reform bill passed last nig... the House takes important steps toward universal ...nd moving our health system from one that focuses ...g people healthy," said Georges C. Benjamin, MD, F...
(Date:11/8/2009)...ail Nation,s Job Creators ,, WASHINGTON, Nov. 8...use passage of the health care bill (H.R. 3962), S...Council) president & CEO Karen Kerrigan issued... those voting for H.R. 3962 voted to burden our na... taxes and penalties. Even in the best of economic...
(Date:11/8/2009)... of biopharmaceuticals to be available at the Comp... Toronto, ON (PRWEB) November ...erapure Biopharma Inc. today announced that the Co...rmaceutical grade freeze dryer and expects to make...vailable for contract manufacturing of biopharmace...
Breaking Medicine News(10 mins):Health News:Few Change Medicare Plans Each Year, But Three Times as Many Are Considering a Change in 2010, Allsup Survey Finds, 2Health News:Few Change Medicare Plans Each Year, But Three Times as Many Are Considering a Change in 2010, Allsup Survey Finds, 3Health News:Few Change Medicare Plans Each Year, But Three Times as Many Are Considering a Change in 2010, Allsup Survey Finds, 4Health News:Few Change Medicare Plans Each Year, But Three Times as Many Are Considering a Change in 2010, Allsup Survey Finds, 5Health News:Breast density associated with increased risk of cancer recurrence 2Health News:APHA Applauds Prevention and Wellness Provisions in House Health Reform Bill 2Health News:Therapure Biopharma Inc. Announces Delivery of its First Commercial-Scale Lyophilizer 2
...tes call on Congress to pass meaningful health ref...on , , WASHINGTON, April 21 With millions of Am... insurance and health care, heart and stroke survi...th their representatives for the American Heart As...
...itute is pleased to welcome Tevi Troy, most recent...d Human Services (HHS) under George W. Bush, as a ...will write on health care, medical innovation, and...ining Hudson at this important juncture," says Hud...
... violence in urban communities show symptoms of po...l effects with a disruption to their normal cortis...ve long-term negative effects on their health. Acc...spital, Harvard Medical School in Boston, USA, bec...
..., , MONMOUTH JUNCTION, N.J., April 21 Transave, ...ent in a Phase II study evaluating the safety and ...inhalation) in non-cystic fibrosis (CF) bronchiect... Presently, there are no approved treatments for t...
...he latest series of wall-mounted diagnostic imagin... attractive covering , , NILES, Ill., April 21 M... images for more than three decades, introduces th...t created a new term when it became the industry,s...
...tronics, Inc. will enhance its Clinical Conductor(...rough integration to Interspond,s RxPaying(TM) deb...yment alternative which improves efficiency and in...ise can be integrated seamlessly. Dan Kerpelman, P...
Other Medicine News:Health News:Healthcare Reform Tops Agenda for Hundreds of Heart Disease and Stroke Survivors on Capitol Hill 2Health News:Former HHS Deputy Secretary Tevi Troy Joins Hudson Institute 2Health News:Witnessing violence affects kids' health 2Health News:Transave Completes Enrollment in Arikace(TM) Phase II Bronchiectasis Study 2Health News:Transave Completes Enrollment in Arikace(TM) Phase II Bronchiectasis Study 3Health News:MAXANT Launches MediPort 3000, The Next-Generation of All-In-One Workstations, on Its Newly Designed Website 2Health News:Bio-Optronics Incorporates RxPaying(TM) Patient Stipend Debit Card Feature in Clinical Conductor(TM) Clinical Trial Management System (CTMS) 2
Centrifuge 4-15C *Avaiable in Europe and Australia*
Centrifuge 4-15C *Available in Japan*
...khorse for the lab, featuring easy-to-use control ...ce. , Product features , , Digital display ... (W x D) footprint fits on a crowded bench, or in ...motor provides maintenance-free operation , Spi...
...Hz, 100/120 V Fast - Powerful g-Force for Fast a...s up to 14,000 rpm (18,000 x g) Ideal for pelleti... Fits on crowded bench or in a cold room Come...able fixed-angle rotor Quiet operation ≤ 58...
Medicine Products: